v3.26.1
Schedule of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Research and development expenses $ 1,464,655 $ 1,226,954 $ 3,801,963 $ 3,392,046
General and administrative expenses 1,326,891 1,540,910 3,296,135 3,521,117
Total operating expenses 2,791,546 2,767,864 7,098,098 6,913,163
Loss from operations $ (2,791,546) $ (2,767,864) (7,098,098) (6,913,163)
Operating Segments [Member]        
Segment Reporting [Line Items]        
Research and development expenses     3,802,000 3,392,000
Change Increase (Decrease), Research and development expenses     $ 410,000  
Change Increase (Decrease), Research and development expenses, percentage     12.10%  
General and administrative expenses     $ 3,296,000 3,521,000
Change Increase (Decrease), General and administrative expenses     $ (225,000)  
Change Increase (Decrease), General and administrative expenses, percentage     (6.40%)  
Total operating expenses     $ 7,098,000 6,913,000
Change Increase (Decrease), Operating expenses     $ 185,000  
Change Increase (Decrease), Operating expenses, percentage     2.70%  
Loss from operations     $ (7,098,000) (6,913,000)
Change Increase (Decrease), Loss from operations     $ (185,000)  
Change Increase (Decrease), Loss from operations, percentage     (2.70%)  
Operating Segments [Member] | Clinical Research [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 1,372,000 1,366,000
Change Increase (Decrease), Subtotal     $ 6,000  
Change Increase (Decrease), Subtotal, percentage     0.40%  
Operating Segments [Member] | Clinical Research [Member] | OVATION Trials [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 347,000 309,000
Change Increase (Decrease), Subtotal     $ 38,000  
Change Increase (Decrease), Subtotal, percentage     12.30%  
Operating Segments [Member] | Clinical Research [Member] | MRD Study [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 96,000 73,000
Change Increase (Decrease), Subtotal     $ 23,000  
Change Increase (Decrease), Subtotal, percentage     31.50%  
Operating Segments [Member] | Clinical Research [Member] | Placcine Vaccine [Member]        
Segment Reporting [Line Items]        
Subtotal     83,000
Change Increase (Decrease), Subtotal     $ (83,000)  
Change Increase (Decrease), Subtotal, percentage     (100.00%)  
Operating Segments [Member] | Clinical Research [Member] | Other Clinical and Regulatory [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 929,000 901,000
Change Increase (Decrease), Subtotal     $ 28,000  
Change Increase (Decrease), Subtotal, percentage     3.10%  
Operating Segments [Member] | Non-Clinical R&D and CMC [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 2,430,000 2,026,000
Change Increase (Decrease), Subtotal     $ 404,000  
Change Increase (Decrease), Subtotal, percentage     19.90%  
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Manufacturing & Clinical Supply [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 2,430,000 $ 2,026,000
Change Increase (Decrease), Subtotal     $ 404,000  
Change Increase (Decrease), Subtotal, percentage     19.90%